key: cord-1053459-3bkg9a9u authors: Paull, Jeremy R.A.; Castellarnau, Alex; Luscombe, Carolyn A.; Fairley, Jacinth K.; Heery, Graham P. title: Astodrimer sodium, dendrimer antiviral, inhibits replication of SARS-CoV-2 in vitro date: 2020-08-21 journal: bioRxiv DOI: 10.1101/2020.08.20.260190 sha: fadaf05375157ac635f2ed1462460eb6577519f5 doc_id: 1053459 cord_uid: 3bkg9a9u An effective response to the ongoing coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will require a range of complementary preventive modalities. The current studies were conducted to evaluate the in vitro SARS-CoV-2 antiviral activity of astodrimer sodium, a dendrimer with broad spectrum antimicrobial activity, including against enveloped viruses in in vitro and in vivo models, that is marketed for antiviral and antibacterial applications. We report that astodrimer sodium inhibits replication of SARS-CoV-2 in Vero E6 cells when added to cells 1-hour prior to or 1-hour post infection, with 50% effective concentrations reducing virus-induced cytopathic effect (EC50) ranging from 0.090 to 0.742 μM (0.002 to 0.012 mg/mL). The selectivity index (SI) in these assays was as high as 2197. Astodrimer sodium was also effective in a virucidal evaluation when mixed with virus for 1 hour prior to infection of cells (EC50 1.83 μM [0.030 mg/mL]). Results from a time of addition study, which showed infectious virus was below the lower limit of detection at all time points tested, were consistent with the compound inhibiting early virus entry steps. The data were similar for all investigations and were consistent with the potent antiviral activity of astodrimer sodium being due to inhibition of virus-host cell interactions, as previously demonstrated for other viruses. Further studies will confirm if astodrimer sodium binds to SARS-CoV-2 spike protein and physically blocks initial association of the virus with heparan sulfate proteoglycans on the host cell. Given the in vitro effectiveness and significantly high SI, astodrimer sodium warrants further investigation for potential as a nasally administered or inhaled antiviral agent for SARS-CoV-2 prevention and treatment applications. The ongoing pandemic coronavirus disease 2019 (COVID-19), caused by severe acute 43 respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, has resulted in unprecedented 44 efforts to rapidly develop strategies to contain infection rates for the protection of vulnerable 45 populations. An effective public health response to the current pandemic will require any vaccine 46 to be supplemented by other alternative preventive modalities. 47 SARS-CoV-2 receptors and coreceptors have been shown to be highly expressed in nasal 48 epithelial cells (Sungnak et al., 2020) . This finding is consistent with the virus infectivity or 49 replication pattern along the respiratory tract, which peaks proximally (nasal cavity) and is 50 relatively minimal in the distal alveolar regions (Hou et al., 2020) . These findings suggest that 51 nasal carriage of the virus could be a key feature of transmission, and that nasally administered 52 therapeutic modalities could be potentially effective in helping to prevent spread of infection. The current studies were conducted to assess the antiviral activity of astodrimer sodium against 69 SARS-CoV-2 in vitro, to determine if it has potential as a reformulated, nasally administered or 70 inhaled antiviral agent to help prevent spread of SARS-CoV-2 infection. Astodrimer sodium was prepared as 86.29 mg/mL in water and stored at 4°C. Astodrimer 81 sodium has a molecular weight of 16581.57 g/mol and the structure is described and illustrated in Astodrimer sodium or remdesivir were serially diluted 1:3, 9 times and each compound 97 concentration was assessed for both antiviral efficacy and cytotoxicity in triplicate. Astodrimer sodium was added to Vero E6 cells 1 hour prior to infection or 1 hour post-99 infection with SARS-CoV-2. Cell cultures were incubated at 37°C in 5% CO2 for 4 days prior Astodrimer sodium was serially diluted 1:3, 9 times and tested in triplicate wells. SARS-CoV-107 2 was mixed with diluted astodrimer sodium at a MOI of 0.05 and incubated for 1 hour at 108 37°C in 5% CO2. Virus and compound mixture were added to Vero E6 cell monolayers in 96-109 well plates and incubated at 37°C in 5% CO2 for 4 days. On day 4, the virus-induced CPE was 110 measured by the MTT assay as described above. The concentration of compound that gives a 50% or 90% reduction in viral-induced CPE (EC50 113 or EC90 respectively) was calculated using the formula of Pauwels et al., 1998. 114 The concentration of compound that resulted in a 50% reduction in cell viability (CC50) after shown individually and as means in Table 1 . 150 The selectivity index (SI) for astodrimer sodium against SARS-CoV-2 ranged from 793 to 2197 151 for the initial assays where compound was added 1 hour prior to infection and 1 hour after 152 infection, respectively, and was >70 to >80 in the repeat assays, in which cytotoxicity was not 153 observed up to the highest concentration tested (0.86 mg/mL). The positive control, remdesivir, was also active in the CPE inhibition assay, with a SI of >33. Astodrimer sodium demonstrated potent antiviral activity against SARS-CoV-2 in Vero E6 cells. The finding of antiviral activity was demonstrated when astodrimer sodium was added to cells or 174 mixed with SARS-CoV-2 prior to infection of cells, when the compound was added to cells 175 already exposed to SARS-CoV-2, and when astodrimer sodium was added at all times 176 throughout the SARS-CoV-2 replication lifecycle to cells already infected with virus. Of note is a significantly high SI for astodrimer sodium relative to other antiviral compounds Virucidal studies of astodrimer sodium determined that it did not disrupt the HIV-1 particle or 211 cause the loss of gp120 spike protein from the viral surface (Telwatte et al., 2011) . The potent antiviral activity of astodrimer sodium against SARS-CoV-2 warrants further 256 investigation. Australia) for the conduct of the assays, collection of data, and provision of materials other than 298 astodrimer sodium. The authors would also like to thank the Peter Doherty Institute for Infection 299 and Immunity (Melbourne, Australia) for the gift to 360Biolabs of SARS-CoV-2 hCoV-300 19/Australia/VIC01/2020 used in these studies. The research was funded by Starpharma Pty Ltd, which was responsible for study design, 303 interpretation of data, writing the manuscript and decision to submit the article for publication. Evaluations of unformulated and 307 formulated dendrimer-based microbicide candidates in mouse and guinea pig models of 308 genital herpes Two phase 312 3, double-blinded, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis A randomized controlled trial of 317 the safety of candidate microbicide SPL7013 gel when applied to the penis Human immunodeficiency virus and heparan sulfate: from 320 attachment to entry inhibition Evaluation 323 of dendrimer SPL7013, a lead microbicide candidate against herpes simplex virus A multibasic cleavage site in the spike 326 protein of SARS-CoV-2 is essential for infection of human lung cells SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a 331 clinically proven protease inhibitor SARS-CoV-2 reverse genetics reveals a 334 variable infection gradient in the respiratory tract Spike mutation pipeline reveals the emergence 343 of a more transmissible form of SARS-CoV-2. bioRxiv Development of a comprehensive human immunodeficiency 348 virus type-1 screening algorithm for discovery and preclinical testing of topical 349 microbicides Inhibition of SARS 352 pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans SARS-CoV-2 355 spike protein binds heparan sulfate in a length-and sequence-dependent manner Dendrimers as drugs: discovery and preclinical Phase 1 randomized trial of the vaginal safety and 363 acceptability of SPL7013 gel (VivaGel ® ) in sexually active young women Human 366 coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells CoV-2) surface protein (spike) S1 receptor binding domain undergoes conformational 371 change upon heparin binding SARS CoV-2 spike S1 receptor binding domain 375 undergoes conformational change upon interaction with low molecular weight heparins Heparin inhibits cellular invasion of SARS-CoV-2: structural heparin Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel ® ): a dose ranging 385 phase 1 study SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaption and 390 cytopathology Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-394 HIV compounds In vitro evaluation of antiviral activity of single and 398 combined repurposable drugs against SARS-CoV-2. Antiviral Res. 104878. Advance 399 online publication The distal polybasic cleavage sites of SARS-CoV-2 spike 401 protein enhance spike protein-ACE2 binding A simple method of estimating fifty percent endpoints Heparan sulfate proteoglycans Results of a phase 3, randomized, double-blind, placebo controlled 409 study to evaluate the efficacy and safety of astodrimer gel for prevention of recurrent 410 bacterial vaginosis SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together 415 with innate immune genes Virucidal 419 activity of the dendrimer microbicide SPL7013 against HIV-1 A phase 2, double-blind, multicenter, randomized, 428 placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimer Gel for the 429 treatment of bacterial vaginosis Structure, 432 function and antigenicity of the SARS-CoV-2 spike glycoprotein Remdesivir and chloroquine effectively inhibit the recently emerged novel 436 coronavirus (2019-nCoV) in vitro Cryo-EM structure of the 2019-nCoV spike in the prefusion 440 conformation A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and 443 SARS-CoV